S. Ros

CheckMate 384: Phase IIIb/IV trial of nivolumab (nivo) 480 mg Q4W versus 240 mg Q2W after ≤ 12 months of nivo in previously treated advanced NSCLC.

N. Reinmuth, K. O'Byrne, S. Rabindran, 2019, Journal of Clinical Oncology.

Whole exome sequencing identifies PLEC, EXO5 and DNAH7 as novel susceptibility genes in testicular cancer

M. Urioste, J. Benítez, C. López, 2018, International journal of cancer.

Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma

I. Chirivella, E. Gallardo, J. Lambea, 2018, BMC Pharmacology and Toxicology.

Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients

B. Mellado, M. Margelí, C. Valverde, 2017, Journal of the National Cancer Institute.

High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1.

L. Paz-Ares, V. Calvo, C. Font, 2020, European journal of cancer.

Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma

I. Chirivella, E. Gallardo, J. Lambea, 2018, BMC Pharmacology and Toxicology.